Your session is about to expire
← Back to Search
Interleukin-2 (IL-2) Agonist
ALKS 4230 for Squamous Cell Carcinoma
Phase 2
Waitlist Available
Research Sponsored by Mural Oncology, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must be willing to provide tumor tissue biopsy
Patients must demonstrate adequate organ function
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time from the first documentation of complete response or partial response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)
Awards & highlights
Study Summary
This trial is testing a new drug combo to see if it can help people with head and neck cancer who haven't responded well to other treatments.
Eligible Conditions
- Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ time from the first documentation of complete response or partial response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time from the first documentation of complete response or partial response, measured approximately every 6 weeks, to the first documentation of objective tumor progression or death due to any cause (estimated up to 24 months)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients with objective evidence of improvement to complete response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy
Disease
Proportion of patients with objective evidence of improvement to partial response among those patients who had disease progression at baseline on prior anti-PD-(L)1 therapy
+1 moreSecondary outcome measures
Duration of response in subjects with CR or PR
Incidence of drug-related AEs
Incidence of drug-related AEs leading to discontinuation
+5 moreSide effects data
From 2024 Phase 2 trial • 57 Patients • NCT0300418321%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Kidney Injury and/or Infection
7%
Pneumonia
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Activated partial thromboplastin time prolonged
5%
Intractable pain, back pain, hip pain
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Skin rash
2%
Thrombocytopenia
2%
Respiratory failure
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm
Trial Design
1Treatment groups
Experimental Treatment
Group I: ALKS 4230 + pembrolizumabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
ALKS 4230
2016
Completed Phase 2
~380
Find a Location
Who is running the clinical trial?
Mural Oncology, IncLead Sponsor
5 Previous Clinical Trials
989 Total Patients Enrolled
Alkermes, Inc.Lead Sponsor
113 Previous Clinical Trials
26,722 Total Patients Enrolled
Immune Oncology NetworkUNKNOWN
1 Previous Clinical Trials
31 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger